Pharmacokinetic Considerations in the Treatment of Inflammatory Bowel Disease

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.40, Iss.10, 2001-01, pp. : 723-751

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment

Current Drug Targets, Vol. 19, Iss. 7, 2018-04 ,pp. : 757-776

Bentham Science Publishers

Access to resources Recommend Favorite

Mesalazine for the treatment of inflammatory bowel disease

By Criscuoli Valeria

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 12, 2013-08 ,pp. : 1669-1678

Informa Healthcare

Access to resources Recommend Favorite

Thiopurine Treatment in Inflammatory Bowel Disease

By Gardiner Sharon J.

Clinical Pharmacokinetics, Vol. 46, Iss. 9, 2007-01 ,pp. : 803-804

Adis International

Access to resources Recommend Favorite

Treatment of Inflammatory Bowel Disease in the Elderly: An Update

By Pardi D.S. Loftus Jr E.V. Camilleri M.

Drugs & Aging, Vol. 19, Iss. 5, 2002-05 ,pp. : 355-363

Adis International

Access to resources Recommend Favorite

The use of tacrolimus in the treatment of inflammatory bowel disease

By Chow Dorothy KL Leong Rupert WL

Expert Opinion on Drug Safety, Vol. 6, Iss. 5, 2007-09 ,pp. : 479-485

Informa Healthcare

Access to resources Recommend Favorite